92,010 Shares in Amneal Pharmaceuticals, Inc. $AMRX Purchased by Tudor Investment Corp ET AL

Key Points

• Tudor Investment Corp ET AL established a new position of 92,010 shares of Amneal Pharmaceuticals in Q3 (about $921,000), with institutional investors now owning roughly 31.82% of the company.
• AMRX trades near $13.12 with a market capitalization of $4.13 billion, a price-to-earnings ratio of 57.05, and a 12‑month range of $7.01 to $15.42.
• Analyst coverage is mixed-to-positive: five Buys and two Holds yield a consensus "Moderate Buy" and a $14.20 target, while Truist recently raised its target to $17 and maintained a Buy rating.

Tudor Investment Corp ET AL bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 92,010 shares of the company's stock, valued at approximately $921,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Comerica Bank raised its holdings in Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company's stock worth $30,000 after acquiring an additional 1,957 shares in the last quarter. Exchange Traded Concepts LLC bought a new stake in Amneal Pharmaceuticals during the third quarter worth about $31,000. Focus Partners Wealth bought a new stake in Amneal Pharmaceuticals during the third quarter worth about $42,000. Advisory Services Network LLC bought a new stake in Amneal Pharmaceuticals during the third quarter worth about $50,000. Finally, Bellevue Group AG bought a new stake in Amneal Pharmaceuticals during the third quarter worth about $79,000. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Stock Up 2.3%

NASDAQ:AMRX opened at $13.12 on Wednesday. The stock's 50 day moving average price is $13.30 and its two-hundred day moving average price is $12.42. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of 57.05 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a 12-month low of $7.01 and a 12-month high of $15.42.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AMRX shares. Truist Financial upped their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. Zacks Research lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $14.20.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.